Oragenics Terminates Material Definitive Agreement
Ticker: OGEN · Form: 8-K · Filed: Nov 29, 2024 · CIK: 1174940
Sentiment: neutral
Topics: material-agreement-termination, filing
TL;DR
Oragenics terminated a key deal, filing 8-K today.
AI Summary
Oragenics, Inc. filed an 8-K on November 29, 2024, reporting the termination of a material definitive agreement as of November 26, 2024. The filing also includes financial statements and exhibits.
Why It Matters
The termination of a material definitive agreement could significantly impact Oragenics' ongoing operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business changes or disputes that could affect the company's future performance.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- November 26, 2024 (date) — Date of earliest event reported
- November 29, 2024 (date) — Date of report
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the exact name or details of the terminated material definitive agreement, only that it occurred on November 26, 2024.
What are the implications of this termination for Oragenics?
The filing indicates the termination is a significant event, but does not detail the specific business or financial implications.
When did the termination of the agreement become effective?
The termination was effective as of November 26, 2024.
Are the financial statements included in this filing related to the terminated agreement?
The filing states that financial statements and exhibits are included, but does not specify their direct relation to the terminated agreement.
What is Oragenics, Inc.'s primary business?
Oragenics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-11-29 17:00:09
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-048190.txt ( ) — 211KB
- ogen-20241126.xsd (EX-101.SCH) — 3KB
- ogen-20241126_lab.xml (EX-101.LAB) — 33KB
- ogen-20241126_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this November 29, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer